Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BF844 in Healthy Volunteers
NCT06592131Phase 1Not yet recruiting
- Sponsor
- EyeXCel
- Start
- Sep 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BF844 in Usher syndrome type 3 (9 cohorts), sponsored by EyeXCel. Primary endpoint: Safety and tolerability of BF844 at 14 Days. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
BF844
03
Conditions
Usher syndrome type 3
Beyond the preview
Go deeper on NCT06592131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592131.